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Abstract. The junctional adhesion molecule (JAMs) family 
belongs to the immunoglobulin subfamily involved in the 
formation of tight junctions (TJ) in both endothelial and 
epithelial cells. Aberrant expression of JAM-2 is associated 
with cancer progression but little work has been carried out 
in discovering how this affects changes in cell behaviour. The 
present study aimed to examine the expression of JAM-2 in 
human colon cancer specimens and cell lines and its role in 
the development of colon cancer. JAM-2 expression in human 
colon cancer specimens (normal, n=75; cancer, n=94) and 
cell lines was analysed using quantitative real-time PCR and 
conventional RT-PCR. Colon cancer cells were stably trans-
fected with a mammalian expression vector to overexpress 
JAM-2-Flag. The effect on growth, adhesion and migration 
following overexpression of JAM-2 was then investigated 
using in vitro models. TJ function was assessed using a trans-
epithelial resistance assay (TER, with an EVOM voltammeter). 
JAM-2 was lowly expressed in colon cancer cells such as RKO, 
HT115. JAM-2 overexpression in RKO cells (RKO-JAM-2) 
and HT115 cells (HT115-JAM-2) showed retarded adhesion 
(P<0.05). An in vivo tumour model showed that RKO-JAM-2 
had significantly reduced growth (P<0.05), invasion (P<0.05) 
and migration (P<0.05) as well as in HT115-JAM-2, except 
on proliferation and migration. Expression of JAM-2 resulted 
in a significant increase in TER and decrease in permeability 
of polarized monolayers (P<0.05). Further analysis of JAM-2 
transcript levels against clinical aspects demonstrated that the 
decreasing JAM-2 expression correlated to disease progres-
sion, metastasis and poor survival. Taken together, JAM-2 may 
function as a putative tumour suppressor in the progression 
and metastasis of colorectal cancer.
Introduction
Colorectal cancer (CRC), one of the most common malig-
nancies, is the fourth leading cause of cancer-related death 
globally (1). In China, there is an increasing trend in both 
morbidity and mortality rates of CRC (2). Although early 
diagnosis and enhanced surgical resections have increased 
survival rates in patients who are diagnosed with CRC, almost 
50% of patients with CRC will die due to complications asso-
ciated with metastasis (3). Understanding the mechanisms of 
metastatic disease has important implications in formulating 
the treatment and metastatic prevention strategies.
The junctional adhesion molecule (JAMs) family belongs 
to an immunoglobulin subfamily involved in the formation of 
tight junctions (TJ) in both endothelial and epithelial cells and 
are characterized by two immunoglobulin-like domains (V-C2 
type Ig domains) (4,5). There are four main members of the 
JAM protein family, which have been named; JAM-A, JAM-B, 
JAM-C and JAM-L (6). Junctional adhesion molecule-B (JAM-
B), also known as JAM-2, is specifically localized to cell-cell 
contacts and enriched at TJ with homotypic interactions. It is 
mainly expressed in the heart, endothelium, trophoblasts of the 
placenta, high endothelial venules and in the endothelium of 
arterioles (7,8). JAM-2 has multiple functions involved in regu-
lation of endothelial and epithelial paracellular permeability, 
leukocyte recruitment during inflammation, angiogenesis, cell 
proliferation and migration (9).
The hallmarks of a metastatic cancer cells are their ability 
to seperate from the original tumour and enter the circulation 
via intravasation, leading to the development of tumour metas-
tasis, anaplasia of the primary tumour or lymphovascular 
invasion (10). The metastatic and invasive cascade consists 
of many complex cellular interactions and pathways (11). 
Approximately 90% of all cancer patients experience tumour 
metastasis (12). Due to the role JAM-2 plays in integrity of 
junctions between cells, it has become an interesting target for 
Effect of junctional adhesion molecule-2 expression on 
cell growth, invasion and migration in human colorectal cancer
HUIsHAN ZHAO1-4*,  HEFEN YU1-3*,  TRACEY A. MARTIN4, 
YUxIANG ZHANG1-3,  GANG CHEN1-3  and  WEN G. JIANG2-4
1Department of Biochemistry and Molecular Biology, school of Basic Medicine, Capital Medical University, Beijing 100069; 
2Cancer Institute of Capital Medical University, Beijing 100069; 3Beijing Key Laboratory for Cancer 
Invasion and Metastasis Research, Beijing 100069, P.R. China; 4Cardiff-China Medical Research 
Collaborative, Cardiff University school of Medicine, Heath Park, Cardiff CF14 4xN, UK
Received October 1, 2015;  Accepted November 5, 2015
DOI: 10.3892/ijo.2016.3340
Correspondence to: Professor Wen G. Jiang, Cardiff-China 
Medical Research Collaborative, Cardiff University school of 
Medicine, Heath Park, Cardiff CF14 4xN, UK
E-mail: jiangw@cf.ac.uk
*Contributed equally
Key words: metastasis suppressor gene, JAM-2, tight junction, 
colorectal cancer, migration, invasion, MMP, trans-epithelial 
resistance
ZHAO et al:  JAM-2 IN COLORECTAL CANCER930
further research. It has been reported that JAM-2 interacts with 
JAM-3 in leukocytes involved in leukocyte trafficking (13-15). 
It has been shown that JAM-2 can regulate invasion and metas-
tasis of melanoma with the expression of JAM-3 (16). Also, 
JAM-2 increases JAM-3-dependent gastric adenocarcinoma 
tumor metastasis (17). Moreover, JAM-2 interferes with the 
signaling pathway of angiogenic VEGF/VEGFR2 (18). A 
previous study suggested that JAM-2 plays an important role 
in regulating tumor growth and angiogenesis (19). An inter-
esting finding was that JAM-2 has low expression in colorectal 
cancer due to hypermethylation of its promotor (20,21). In this 
study we used JAM-2 overexpression in colon cancer cells to 
study its role in the development of colon tumour progression.
Materials and methods
Human colorectal specimens. A total of 169 patient tissues 
(94 were colorectal cancer tissues; 75 were normal background 
tissues) were collected immediately after surgery and snap- 
frozen in liquid nitrogen until further use. Background normal 
mammary tissues were gained from the same patients. The 
size of tumour tissues and normal tissues was confirmed by 
a pathologist and the background tissues were free of tumour 
deposits. All protocols were approved by the local ethics 
committee. Full details of patient clinical data are shown in 
Table I.
Cell culture. RKO and HT115 human cancer cell lines were 
acquired from the European Collection of Animal Cell 
Cultures (ECACC; salisbury, UK). These two wild-type cells 
were routinely cultured in DMEM/F12 HAM (Dulbecco's 
modified Eagle's medium; Sigma-Aldrich) supplemented with 
10% fetal calf serum (FCs; PAA Laboratories, somerset, UK), 
penicillin and streptomycin (sigma-Aldrich), in an incubator 
at 37.0˚C, 95% humidity and 5% CO2.
Construction of JAM-2 expression vectors and transfection. 
The JAM-2-GFP and pCMV-entry plasmids were purchased 
from OriGene Technoloqies (Rockville, MD, UsA). The JAM-2 
cDNA sequences which were obtained from the JAM-2-GFP 
plasmid were individually cloned into a mammalian expres-
sion pCMV-entry plasmid vector. Purified JAM-2 transgenes 
and control plasmid vectors were transfected into RKO and 
HT115 cells respectively using an Easjet Plus electroporator 
(EquiBio Ltd., Kent, UK).
RNA isolation and reverse transcription PCR. RNA was 
isolated from wild-type and selected cells using total-RNA 
isolation reagent (sigma-Aldrich, Dorset, UK). Following 
the manufacturer's protocol, cDNA was generated from the 
total RNA using Goscript™ Reverse Transcription system 
kit (Promega, Madison, WI, UsA). subsequently, PCR was 
conducted using a REDTaq™ ReadyMix PCR reaction mix 
(primer sequences shown in Table II). Reaction conditions 
were: 94˚C for 5 min (initial denaturation), followed by 35 
cycles of 94˚C for 30 sec, 55˚C for 30 sec and 72˚C for 40 sec. 
This was followed by a final 10-min extension period at 72˚C. 
The products were visualized on 2% agarose gel stained with 
ethidium bromide. Quantitative analysis of the JAM-2 tran-
script was carried out using real-time quantitative PCR with 
on the Amplifluor™ technology. Q-PCR primers (Table II) 
were designed using Beacon Design software (Premier 
Biosoft, Palo Alto, CA, UsA), and one of the primers carried 
a Z-sequence. Colorectal cDNA samples were synchronously 
examined for JAM-2 and GAPDH along with a set of internal 
control. Real-time PCR was carried out using iCycler iQ™ 
(Bio-Rad Laboratories, Hemel Hempstead, UK) following 
the cycling conditions: 94˚C for 5 min, 70 cycles of: 94˚C for 
10 sec, 55˚C for 35 sec and 72˚C for 20 sec.
Western blot analysis. Total protein concentrations were 
determined with the DC Protein Assay kit (Bio-Rad 
Laboratories, Hertfordshire, UK) and an ELx800 spectropho-
tometer (Elx800 ™; Bio-Tek, swindon, UK). Equal amounts 
of protein sample were separated using 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (sDs-PAGE) and 
blotted onto PVDF membrane. Following protein transfer, 
the membrane was blocked with 5% skimmed milk for 1 h. 
Proteins were then separately probed with the polyclonal 
goat anti-human JAM-2 antibody (R&D systems, Inc., 
Minneapolis, MN, UsA), monoclonal mouse anti-human 
GAPDH antibody (BD Biosciences, san Diego, CA, UsA) and 
corresponding peroxidase-conjugated secondary antibody. 
Protein bands were visualized and analysed using Luminata 
Forte (Merck Millipore, Hertfordshire, UK) and an UVITech 
imager (UVITech, Inc., Cambridge, UK).
In vitro cell function assays
In vitro cell growth assay. Cell suspensions were added into 
a 96-well plate (3,000 cells/200 µl/well). Cell growth was 
assessed after a period of incubation (up to 5 days) in quadru-
plicate (overnight, day 3, day 4 and day 5). Cells were fixed in 
4% formalin and stained with 0.5% crystal violet. Crystal violet 
was extracted with 10% (v/v) acetic acid and the absorbance of 
the dissolved dye determined using an ELx800 spectropho-
tometer (ELx800; Bio-Tek) at a wavelength of 540 nm.
In vitro cell migration assay. Cells (700,000/well) were seeded 
in a 24-well plate and cultured in the incubation overnight, 
then scratched with a 10-µl pipette tip to create a wound and 
washed twice with PBS to remove floating cells. The cells 
were photographed at intervals using an inverted microscope; 
the size of the wounds were subsequently measured with the 
ImageJ software.
In vitro cell adhesion assay. Plates (96-well) were pre-coated 
with Matrigel (BD Matrigel™ Basement Membrane Matrix) 
(5 µg/100 µl/well) diluted with serum free media and dried. 
Following rehydration with serum-free media 40,000 cells 
were added into each well. After incubation for 40 min, the 
wells were washed with Bss to remove non-adherent cells and 
the adherent cells were fixed with 4% formalin and stained 
with 0.5% crystal violet. Crystal violet staining was dissolved 
with 10% acetic acid and measured using a spectrophotometer 
(Elx800; Bio-Tek).
In vitro cell invasion assay. Transwell inserts with an 8 µm pore 
size were coated with 50 µg Matrigel/100 µl (BD Matrigel™ 
Basement Membrane Matrix) and air-dried. Following rehy-
dration, 30,000 cells/200 µl/well were added with 0.5% FCs 
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Table I. Correlation of mRNA of JAM-2 and clinical parameters.
Category No. Median IQR P-value
T/N
  Normal 75 6.4 <0.000001-616
  Tumour 94 <0.000001 <0.000001 0.042
Paired T-N
  Paired normal 68 6.4 <0.000001-525
  Paired tumour 68 <0.000001 <0.000001-0.01 0.03
Location
  Left colon 22 <0.000001 <0.000001-0.01
  Right colon 28 <0.000001 <0.000001
  Trans-colon 2 0.00175 N/A
  Rectum 22 <0.000001 <0.000001
Dukes' stage
  A 7 <0.000001 <0.000001-0.0008
  B 33 3.19 <0.000001-0.01 0.2
  C 32 12.8 <0.000001 0.34
  BC 65 7.93 <0.000001-0.01 0.17
Tumour stage
  T1 2 <0.000001 N/A
  T2 10 <0.000001 <0.000001-0.00745 0.19
  T3 40 <0.000001 <0.000001-0.03 0.25
  T4 18 <0.000001 <0.000001 0.36
  T23 50 <0.000001 <0.000001-0.02 0.09
  T34 58 <0.000001 <0.000001-0.01 0.27
Lymph node involvement stage
  N0 39 <0.000001 <0.000001-0.01
  N1 16 <0.000001 <0.000001-0.6 0.33
  N2 15 <0.000001 <0.000001-0.028 0.19
TNM stage
  Ⅰ 9 <0.000001 <0.000001-0.01
  Ⅱ 30 <0.000001 <0.000001-0.01 0.54
  Ⅲ&Ⅳ 32 <0.000001 <0.000001 0.32
Clinical outcome
  No invasion 50 <0.000001 <0.000001-0.01
  Invasion 26 <0.000001 <0.000001
  Disease free 35 0.001 <0.000001-0.012
  Incidence 23 <0.000001 <0.000001-0.32
  No metastasis  50 <0.000001 <0.000001-0.008
  Alive 36 <0.000001 <0.000001-0.009
  Died 22 <0.000001 <0.000001-0.17
Table II. Primer sequences.
Molecule sense primers (5'-3') Antisense primers (5'-3')
JAM-2 (Q-PCR)  TGATAGGGGCTGTAAATCT ACTGAACCTGACCGTACATAATGATGCAAGACAGTTCC
GAPDH (Q-PCR) CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG
JAM-2  GAACTGTGGTAGAGCTACGATGTC TTTCACTCATTGTCGTGGCTTTAG
GAPDH GGCTGCTTTTAACTCTGGTA GACTGTGGTCATGAGTCCTT
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and 1 ml with 10% FCs medium in the bottom well. After 48 h, 
the cells that migrated through the matrix and pores were fixed 
with 4% formalin, stained in crystal violet and analyzed.
Transepithelial resistance (TER). TER was measured with an 
EVOM Volt-Ohm meter (EVOL, World Precision Instruments, 
Aston, Herts, UK) with sTx2 electrode (World Precision 
Instruments, Inc., sarasota, FL, UsA). Briefly, cells were 
added into the 0.4-µm pore size insert (Greiner Bio-One 
Ltd., Stonehouse, UK) and allowed to reach full confluency. 
Electrodes were placed at the upper and lower chambers, then 
resistance was measured with the Volt-Ohm meter. Fluorescein 
isothiocyanate (FITC)-dextran 10 kDa and TRITC dextran 
40 kDa were applied to cells apically. Basolateral dextran 
passage was analyzed with a GloMax®-Multi Microplate 
Multimode reader (Promega UK Ltd., southampton, UK).
Gelatin zymography assay. Cells (1x106) were seeded into a 
tissue culture flask and cultured in serum-free medium. After 
6 h, samples were centrifuged (4,000 rmp for 10 min) to remove 
cell debris. The supernatant was collected and centrifuged for 
15 min (14,000 x g) in Amicon Ultra-0.5 ml centrifugal filters 
(Merck Millipore, East Midlands, UK). Thereafter, the sample 
was separated via 10% sDs-PAGE containing 0.1% gelatin. 
Following electrophoresis, gels were washed and incubated 
overnight at 37˚C. After incubation, gels were stained with 
Coomassie blue and ubsequently scanned on digital scanner 
images (sNP-id 2.0 machine; Millipore UK Ltd., Watford, 
UK) and digital data were saved for analysis.
Statistical analysis. Experimental procedures were repeated 
independently at least 3 times. statistical analysis was 
performed using the Minitab statistical software package 
(version 14). Data with a non-parametric distribution were 
assessed with the Mann-Whitney U test, whilst a two sample 
t-test was used for normally distributed data. Differences were 
considered to be statistically significant at P<0.05.
Results
JAM-2 expression in colorectal cancer cells and tissues. The 
expression of JAM-2 was examined in colon cancer cell lines 
and a cohort of colon tumour tissues using reverse transcrip-
tion-PCR. We found that JAM-2 exhibited very low expression 
in all four colon cancer cell lines and in colon cancer tissues 
which were selected randomly (Fig. 1A). JAM-2 transcript 
levels were quantified in the colon specimens (tumour, n=94; 
background, n=75) using real-time quantitative PCR (all values 
displayed as mean JAM-2 transcript copies/µl of cDNA from 
50 ng total RNA). In comparison with normal colon tissues, 
a significantly decreased expression (P=0.042) of JAM-2 was 
observed in tumour tissues (Fig. 1B).
Correlation of JAM-2 expression in colorectal adenocarci-
noma and of the clinical characteristics of the disease. JAM-2 
transcripts were analysed in colorectal cancer tissues and 
adjacent normal tissues using Q-RT-PCR. Decreased levels of 
JAM-2 demonstrated a lower level in tumours than in normal 
background tissues (P=0.03). The expression level of JAM-2 
decreased as TNM stage (P=0.32) and nodal stage (P=0.19) 
and levels of JAM-2 transcript were lower in node- positive 
Figure 1. Expression of JAM-2 in colon cancer cells and tissues. (A) The 
mRNA levels of JAM-2 in colon cancer cell lines were barely detect-
able. (B) JAM-2 mRNA levels were decreased in colon cancer tissues. 
(C) Expression of JAM-2 in colon cancer tissues. JAM-2 transcript level was 
decreased significantly in human colon cancer. *P<0.05.
Figure 2. Overexpression of JAM-2 in colon cancer cells. (A) Expression of 
JAM-2 in RKO and HT115 cells were verified using RT-PCR. (B) Expression 
of JAM-2 in RKO and HT115 cells was verified using western blotting.
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tumours than in node-negative tumours, lower in tumours 
with distant metastasis than those without metastasis, and 
much lower in the patients who had died of colon cancer than 
in those who remained alive and well, but this did not reach 
statistical significance. Medical notes and histology reports 
were used to extract clinico-pathological data (Table I).
Expression of JAM-2 in colon cancer cell lines reduces cell 
growth, adhesion, migration and invasion. To study the role 
of JAM-2 in colon cancer metastasis and progression, we over-
expressed JAM-2 in RKO and HT115 cells. We confirmed that 
JAM-2 plasmid had successfully expressed JAM-2 within the 
RKO and HT115 colon cancer cell lines (Fig. 2). RT-PCR and 
western blot data demonstrated that JAM-2 was expressed at 
mRNA and protein level in comparison to the level of expres-
sion in the empty plasmid control cells (RKOpCMV-entry and 
HT115pCMV-entry) and in wild-type cells (RKOWT and HT115WT) 
(Fig. 2).
Compared with the pCMV-entry control, JAM-2 expres-
sion caused a significant reduction of RKO cell growth 
Figure 3. The effect of forced JAM-2 expression on biological functions of colon cancer cells. (A) Forced JAM-2 expression inhibited the in vitro growth of 
RKO cell and had little effect on HT115. (B) Forced JAM-2 expression in RKO cells had inhibitory effect on RKO cell motility had not significant effect on 
HT115. (C) Forced JAM-2 expression reduced cell-matrix adhesion of colon cancer cells. (D) Forced JAM-2 expression decreased invasion of colon cancer 
cells. shown are representative results of three independent experiments of each function assay. **P<0.01, *P<0.05.
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(P<0.01) but not in HT115 (P>0.05) cells, however, the growth 
trend of the two cell lines was similar (Fig. 3A). The migration 
assay showed that expression of JAM-2 in RKO cells resulted 
in a strong reduction in the degree of migration (P<0.01 vs. 
pCMV-entry control) (Fig. 3B) but did not result in a signifi-
cant change on HT115 cells. We also determined the influence 
on cell adhesion. Expression of JAM-2 decreased adhesion of 
the colon cancer cell lines and produced a significant change in 
Figure 4. MMP-9 expression after JAM-2 overexpression. Zymography showed that forced JAM-2 expression led to decreased secretion of MMP-9 by RKO 
and HT115 cells.
Figure 5. Effect of JAM-2 on the behaviour of RKO and HT115 cells. (A) JAM-2 expression increased the TER in both RKO and HT115 monolayer in com-
parison to that in empty plasmid control cells. (B) JAM-2 inhibits FITC flux of RKO and HT115 monolayer. (C) JAM-2 expression decreased permeability of 
polarized monolayers of RKO and HT115 cells in TRITC.
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both RKO and HT115 cells (P<0.01 vs. pCMV-entry control) 
(Fig. 3C). Moreover, invasion data suggest that increasing 
JAM-2 expression depressed colon cancer cells invasion 
(P<0.01 vs. pCMV-entry control) (Fig. 3D).
Expression of JAM-2 influences MMP activity in colon cancer 
cells. Invasive potential relates to the ability of tumour cells to 
degrade the extracellular matrix. We used gelatin zymography 
on supernatants from RKO and HT115 JAM-2 expression 
cells, which showed a decrease in MMP9 activity compared 
with pCMV-entry control cells (Fig. 4).
Expression of JAM-2 decreases the trans-epithelial resistance 
(TER) and the permeability of polarized monolayers. We next 
examined the effect of JAM-2 overexpression on TJ barrier 
function. JAM-2 had a significant effect on the TJ function of 
colon cancer cells. TER in both RKO and HT115 with JAM-2 
expression cells were reduced, in comparison to that in empty 
plasmid control cells (RKOpCMV-entry and HT115pCMV-entry) and 
in wild-type cells (RKOWT and HT115WT) (P<0.01; Fig. 5A). 
In order to verify the TER results, we also detected the flux 
between polarized cells monolayers using paracellular perm-
ability. This demonstrated that the higher the TER, the lower 
the permeability of polarized monolayers was with both FITC 
dextran 10 kDa and TRITC dextran 40 kDa (Fig. 5B and C).
Discussion
In the present study, we demonstrated that JAM-2 has low 
expression in colon cancer which is consistent with previous 
studies, where it was shown that JAM-2 is downregulated 
due to the JAM-2 gene having a hyper-methylated promoter 
at the CpG islands (20,22). We have also shown that JAM-2 
expression exerts a significant effect on tumour metastasis and 
invasion. JAM-2 expression decreases the invasive properties 
of RKO and HT115 colon cancer in vitro, leading to reduced 
MMP9 activity.
Regarding to the role of JAM integrity at the junctions 
between cells, some studies have focused on the expression 
analysis of the JAM-2 gene in different cancers. Recently, a 
report showed that the mRNA level of JAM-2 was deregu-
lated in gastric cancer (17). Another study found that JAM-2 
occurred in primary cancer compared to chronic gastritis and 
metastatic cancer (23). Taken together, JAM-2 expression in 
glioma suggests that JAM-2 may play a role in cancer metas-
tasis by decreasing the expression of actin filament-associated 
protein through interacting with JAM-3. Arcangeli et al (16) 
have shown that JAM-2 expression in endothelial cells 
contributed to murine B16 melanoma cell metastasis through 
interacting with JAM-C on tumour cells. The present study 
also detected the expression of JAM-2 in relation to colorectal 
cancer patient clinical data in a cohort of human colorectal 
cancer specimens through quantitative PCR. Reduced 
transcript expression of JAM-2 was observed in the colon 
cancer tissue sections in comparison to normal background 
mammary tissues (P=0.042). This indicated that a loss of 
JAM-2 may occur as cells and normal tissues progress to a 
cancerous state.
Following overexpression of JAM-2 in colon cancer cells, 
analysis of functional studies revealed a statistically signifi-
cant reduction in JAM-2 expression in RKO cells as compared 
to controls in growth, migration, adhesion and invasion. This 
occurred in HT115 cells, although the effect on proliferation 
and migration was not as substantial. Cell-matrix adhesion 
plays a key step in cancer metastasis and is essential for inva-
sion through matrix so as to progress the metastatic process.
Numerous studies suggest matrix metalloproteases 
(MMP), a family of multidomain, zinc-containing neutral 
endopeptidases, to contribute to form a microenvironment 
that promotes tumour metastasis during early stages of 
tumourigenesis (24,25). Degradation of extracellular matrix 
components containing laminin, proteoglycans, collagen and 
other glycoproteins by MMPs facilitates proliferation, migra-
tion and metastasis of cancer cells, via blood and lymphatic 
routes (26). MMP-9-induced release of biological mediators 
from the extracellular matrix surrounding a cancer may 
compose a system by which stromal and neoplastic cells 
communicate. MMP-2 and MMP-9 are important members 
of MMPs family and their role has been studied in colon 
cancer (27). MMP-9 has been related to tumour progression in 
numerous studies (28-32). MMP-9 is regarded as an extreme 
enzyme for damage of the basement membrane, the first barrier 
for tumour invasion. some studies have demonstrated that it is 
associated with tumour metastasis (33,34). Our study shows 
that MMP-9 is downregulated in JAM-2 overexpressing cells, 
which is consistent with the decreased invasive capability of 
JAM-2 expression in colon cancer cells.
JAM-2 is involved in the formation of TJs, with increased 
TER and decreased permeability in several cell types. In this 
study, resistance in both RKO and HT115 monolayer was 
reduced with JAM-2 overexpression in comparison to the 
empty plasmid control cells. Overall, JAM-2 decreased the 
permeability of polarized monolayers.
In conclusion, we characterized a pattern of low expres-
sion of JAM-2 in colon cancers which was correlated with 
metastasis of colorectal cancer. With cells overexpressing 
JAM-2, we found that JAM-2 can inhibit tumour metastasis 
by reducing invasion. This study also showed that overexpres-
sion of JAM-2 inhibits the invasive potential of cancer cells by 
regulating the transcription of MMP-9. JAM-2 provides a new 
research direction for the diagnosis and treatment of relevant 
diseases.
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